🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

David B. Zhen

University of Washington

ORCID: 0000-0003-3375-5912

Also affiliated with Fred Hutch Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients”.

The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients

Journal of Geriatric Oncology(2023)10.1016/j.jgo.2023.101474

N/A

0.693DataRank · unranked

18 citations

Paul J. Catalano, Leon Lenchik, Robert D. Boutin, Xin Yao, Helga S. Marques +8 more

Homologous recombination deficiency (HRD) by BROCA-HR and survival outcomes after surgery for patients (pts) with pancreatic adenocarcinoma (PC): A single institution experience.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.4_suppl.732

N/A

0.104DataRank · unranked

1 citations

David B. Zhen, Marc R. Radke, Kelsey K. Baker, Andrew L. Coveler, Kit Man Wong +5 more

SWOG S2012: Randomized phase II/III trial of first line platinum/etoposide (P/E) with or without atezolizumab (NSC#783608) in patients (pts) with poorly differentiated extrapulmonary small cell neuroendocrine carcinomas (NEC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps4179

N/A

0DataRank · unranked

5 citations

Edward Mayerson, E. Gabriela Chiorean, Earle F. Burgess, Elizabeth M. Swisher, Carl M. Gay +9 more

A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186—Trials in progress.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps4185

N/A

0DataRank · unranked

0 citations

Paul J. Catalano, Leon Lenchik, Robert D. Boutin, Xin Yao, Shaalan Beg +9 more